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Briefly, we distinguish two cystinuria subtypes: Type I
Dialysis and protein and non-type I. Those patients whose urinary cystine
excretion was more than 1000 mmol cystine/gram creati-
malnutrition nine were classified as homozygotes. Non-type I hetero-
zygotes showed urinary excretion of at least one of the
To the Editor: Two recent conferences have addressed
amino acids cystine, lysine, arginine and ornithine, and
(among other topics) the issues of when to start dialysis the sum of cystine plus dibasic amino acids is higher than
and how to prevent protein malnutrition in patients ap- normal values. We cannot distinguish between type II
proaching end-stage renal disease. These were the Na- and type III heterozygotes. We have started genetic stud-
tional Kidney Foundation “Dialysis Outcomes Quality ies in these patients and their relatives. Preliminary re-
Initiative” and a conference in Washington entitled sults show that all the patients who had formed kidney
“Strategies for Influencing Outcomes in Pre-ESRD and stones have high levels of urinary cystine (.3000 mmol
ESRD Patients.” The consensus of both meetings was cystine/gram creatinine) but surprisingly some of our
that: (1) pre-ESRD protein restriction is dangerous; and patients with the same levels who are already in adult-
(2) dialysis should be initiated as soon as the glomerular hood have not formed stones. There are also some cases
filtration rate falls to about 10 ml/min (or perhaps 20 ml/ that cannot be explained using the phenotypic classifica-
min), especially if spontaneous protein intake decreases. tion. As Goodyer et al emphasized, it is critical to distin-
The basis for these recommendations appears to be guish between the phenotypic and genotypic classifica-
entirely conjectural. Has it been demonstrated, for exam- tion of cystinuria; therefore, after finishing our genetic
ple, that increasing protein intake in pre-dialysis patients epidemiology studies, we may change our initial classifi-
will reduce the alarming incidence of hypoalbuminemia cation to permit better management of cystinuric pa-
at the onset of dialysis? Apparently not. Has it been tients.
demonstrated that protein restriction predialysis ad- With regard to the article by Goodyer et al, it is clear
versely affects the outcome on dialysis? Apparently not. that type I/I homozygotes, in which the authors found
Has it been demonstrated that early dialysis is associated mutations of SLC3A1 gene in seven of the eight patients,
with lower mortality than pre-dialysis care? No. Has have inherited one mutation of each of their parents,
it been demonstrated that the same minimal value for who have normal urinary levels of cystine. On the other
hand, Goodyer et al did not find any mutations, exceptexcretory function that seems to reduce dialysis morbid-
for an SLC3A1 gene mutation, in patients classified asity will reduce predialysis morbidity? No.
type I/III and type II/N. One of the parents of our cysti-The nephrology community has apparently revised its
nuric patients has a urinary cystine level higher thantreatment recommendations on the basis of conjectures.
normal values; therefore we classify him/her as a non-If these conjectures are incorrect (as I believe), the re-
type I heterozygote (type III/N in the Goodyer et alsults could be catastrophic.
classification) or, if the urinary cystine excretion is more
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excretion comparable to that of the affected parent. On ease—after all, nowadays we can modify those easier
than genetic factors. For this reason we need to searchthe other hand, the excretion of cystine in type I/III
further for the possible association between these envi-patients is different from that of the affected parent. We
ronmental factors, studied through valid questionnaireswonder if all these patients, who are born of one normal
about lifestyle, and the risk of nephrolithiasis.parent (with normal values of amino acid urinary excre-
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